2025 has been an important year for mAbsolve. We are pleased to report that two of our commercial licensees have now entered clinical trials using our STR technology. These are significant milestones for the company. Published clinical data from STR-based products has long been the key missing piece needed to accelerate broader adoption of our … Read more
With the grant of additional patents in the USA (US1249744) and Japan (JP7791867), mAbsolve’s patent coverage has been further extended to include nucleic acids and Fc fusion proteins which incorporate the STR technology. These divisional patents build on our existing granted patents in the United States, Japan, United Kingdom, Canada and Australia, which cover antibodies … Read more
Along with our updated website we are also launching the first edition of our company updates. We intend to publish these quarterly to provide regular updates on activities at mAbsolve. As the first such update in two years since our founding this will look back a bit further. The last two years has seen the … Read more
When the company was founded in December 2019 we were a startup with an interesting technology in the early stages of development. Still in stealth mode at the time, a website wasn’t our top priority and so we quickly put something together as a temporary measure. As a company founded and managed by scientists it … Read more
mAbsolve’s international patent application on a novel Fc silencing technology has today been published under application number WO/2021/234402.
Starting today Dr. Ian Wilkinson joins mAbsolve as Chief Scientific Officer, having been a Founder and non-executive Director since the company’s induction in December 2020. Ian brings a wealth of experience in the development and commercialisation of antibody technologies having previously been Chief Scientific Officer at Absolute Antibody, taking that organisation from start-up through to … Read more
mAbsolve has today filed an international patent application PCT/GB2021/051233 on its novel Fc silencing technology.
After a period of research and development mAbsolve today announces the formal launch of its Fc silencing technology named STR. Access to the technology platform will be made available through research and commercial licences. mAbsolve scientists and partners have performed extensive in vitro and in vivo analysis of the Fc mutations collecting demonstrating that STR … Read more
mAbsolve has today filed a patent on its novel Fc silencing technology, GB2007613.9.
A novel Fc silencing technology developed at Absolute Antibody has been formally spun-out into a new business entity – mAbsolve Limited. Prof. Geoff Hale becomes CEO of mAbsolve with Dr. Ian Wilkinson and Dr. Nicholas Hutchings as non-executive directors. mAbsolve will further develop the Fc silencing technology with the ultimate intention of licensing it to … Read more